Samil Pharm Total Liabilities
Samil Pharm total liabilities. Based on the latest financial reports, Samil Pharm (000520) has total liabilities worth ₩226.31 Billion KRW (≈ $153.37 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Samil Pharm to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Samil Pharm (2011–2024)
Total liabilities of Samil Pharm from 2011 to 2024. This chart illustrates how Samil Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore Samil Pharm (000520) long-term investment share to see how much of total assets are deployed in long-term investments.
Samil Pharm Competitors by Total Liabilities
The table below lists competitors of Samil Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WCT Holdings Bhd
KLSE:9679
|
Malaysia | RM4.83 Billion |
|
Davicom Semiconductor Inc
TW:3094
|
Taiwan | NT$104.36 Million |
|
Lastminute.com NV
SW:LMN
|
Switzerland | CHF517.92 Million |
|
O-TA Precision Industry Co Ltd
TWO:8924
|
Taiwan | NT$1.85 Billion |
|
Immunic Inc
NASDAQ:IMUX
|
USA | $30.73 Million |
|
DaeChang Solution Co. Ltd
KQ:096350
|
Korea | ₩110.12 Billion |
|
Rupa & Company Limited
NSE:RUPA
|
India | Rs4.97 Billion |
|
Thien Viet Securities JSC
VN:TVS
|
Vietnam | ₫4.17 Trillion |
Liability Composition Analysis (2011–2024)
This chart breaks down Samil Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Samil Pharm.
Liquidity & Leverage Metrics
Samil Pharm Total Liabilities Ratios Explained
Samil Pharm total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Samil Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Samil Pharm (2011–2024)
The table below shows the annual total liabilities of Samil Pharm from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩218.95 Billion ≈ $148.38 Million |
-9.84% |
| 2023-12-31 | ₩242.85 Billion ≈ $164.58 Million |
+5.19% |
| 2022-12-31 | ₩230.88 Billion ≈ $156.46 Million |
+43.71% |
| 2021-12-31 | ₩160.66 Billion ≈ $108.88 Million |
+25.41% |
| 2020-12-31 | ₩128.11 Billion ≈ $86.82 Million |
+5.35% |
| 2019-12-31 | ₩121.60 Billion ≈ $82.41 Million |
+32.37% |
| 2018-12-31 | ₩91.87 Billion ≈ $62.26 Million |
+8.96% |
| 2017-12-31 | ₩84.31 Billion ≈ $57.14 Million |
+75.19% |
| 2016-12-31 | ₩48.12 Billion ≈ $32.61 Million |
+7.18% |
| 2015-12-31 | ₩44.90 Billion ≈ $30.43 Million |
-15.08% |
| 2014-12-31 | ₩52.88 Billion ≈ $35.83 Million |
+15.75% |
| 2013-12-31 | ₩45.68 Billion ≈ $30.96 Million |
-5.07% |
| 2012-12-31 | ₩48.12 Billion ≈ $32.61 Million |
-11.86% |
| 2011-12-31 | ₩54.60 Billion ≈ $37.00 Million |
-- |
About Samil Pharm
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inf… Read more